



Kilitch Drugs (India) Ltd.

13th March, 2026

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: BSE – 524500

Symbol: NSE - KILITCH

Sub: Proceedings and outcome of Extra-Ordinary General Meeting of Kilitch Drugs (India) Limited held today i.e. Friday, 13th March, 2026

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Extra-Ordinary General Meeting (“EGM”) of the Company was held today i.e. Friday, 13th March, 2026 at 11:30 am through video conferencing. We are enclosing herewith the summary of the proceeding of the EGM for your record.

The details of the voting results along with the Scrutinizer’s Report will be disseminated to the Stock Exchanges and will be placed on the Company’s website, in due course.

The meeting was commenced at 11:30 am and concluded at 11:42 am.

Kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours’ faithfully,

For Kilitch Drugs (India) Limited

Pushpa Nyoupane
Company Secretary



Proceedings of Extra-Ordinary General Meeting of the Company held on Friday, 13th March, 2026

The Extra-Ordinary General Meeting (“EGM”) of the members of Kilitch Drugs (India) Limited was held today i.e. Friday, 13th March, 2026 at 11:30 a.m. through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The meeting was held in compliance with the applicable provisions of the Companies Act, 2013 read with the circulars issued by Ministry of Corporate Affairs and the Securities and Exchange Board of India without physical presence of the members.

Mr. Mukund Mehta, Managing Director, Mrs. Mira Mehta, Managing Director, Mr. Bhavin Mehta, Wholetime Director, Prof. Vasudev Krishna Murti, Independent Director, Mr. Dipen Jain, Independent Director, Mr. Venkita Subramanian Rajan, Independent Director, Mr. Sunil Jain, Chief Financial Officer, Ms. Pushpa Nyoupane, Company Secretary, Mr. Chintan Shah, Proprietor of C Sharat and Associates Statutory Auditors, Mr. Deep Shukla, the Proprietor of Deep Shukla & Associates, Secretarial Auditors and Scrutinizer of the meeting and Mr. Arvind Kumar, Proprietor of Arvind Kumar and Co. Cost Auditors of the Company had joined the meeting.

Participants’ details:

Member attended: members [Promoter and Promoter Group - 3 and Public - 45]

Mr. Mukund Mehta, Managing Director chaired the meeting and since the requisite quorum was present, the meeting was called to order.

Ms. Pushpa Nyoupane, Company Secretary of the Company, with the permission of the Chairman, commenced the meeting by welcoming all attendees and briefing the general instructions regarding the participation in the meeting through video conferencing and remote e-voting as well as voting during the meeting electronically to the members. With the permission of Chairman, the Company Secretary introduced all the panelist with the shareholders.

The Company Secretary informed that all efforts feasible under the circumstances have indeed been made by the Company to enable members to participate and vote on the item being considered in the meeting electronically.

The Company Secretary also informed that pursuant to the guidelines and circulars issued by the Ministry of Corporate Affairs and SEBI Regulations, the facility to appoint proxy by members to attend the meeting and cast vote was not applicable for the EGM as the EGM was convened through VC / OAVM.

Mr. Mukund Mehta addressed the member on performance and business prospect of the Company.

With the permission of members, the Notice convening the EGM which was sent through electronic mode to Members of the Company was taken as read.

The following items of business, as per the Notice convening the EGM of the Company, were transacted at the meeting:





Kilitch Drugs (India) Ltd.

Resolution No. 1 – To increase authorize capital of the Company and amend the Capital Clause of Memorandum of Association

Resolution No. 2 - to approve issue and allotment of Bonus Shares in the ratio of 1:1 to the existing shareholders of the Company as on the record date to be decided by the Board of Directors.

As registered speaker shareholder did not attend the meeting, the meeting was concluded at 11:42 am with the vote of thanks.

For **Kilitch Drugs (India) Limited**

Pushpa Nyoupane
Company Secretary

